Clinical Trials

Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660

Rebiotix and Ferring are the first to announce positive preliminary results on primary efficacy endpoint from ongoing pivotal Phase 3 clinical trial for RBX2660 RBX2660 is an investigational, non-antibiotic, microbiome-based therapy, developed to reduce Clostridiodes difficile (C. diff) infection recurrences CDC defines C. diff as a major burden to patients and doctors and an urgent […]

Francis Medical Moving Forward in the Age of COVID-19

Via Francis Medical “Like most companies, Francis Medical is facing several unique challenges brought on by the coronavirus pandemic. However, unlike many companies facing the prospect of lost revenues, the real enemy of a pre-revenue startup company, like Francis Medical, is lost time. ‘Every day of delay to our timeline could mean one day later […]

Prism Clinical Research collaborates with University of Minnesota researchers in COVID-19 prevention treatment study for healthcare workers

Prism Clinical Research (a Nucleus Network company) is playing a key role in supporting the University of Minnesota as it commences trialling a COVID-19 prevention treatment targeting frontline healthcare workers and first responders.  David Boulware, MD, MPH, a professor in the University of Minnesota Medical School’s Department of Medicine in the Division of Infectious Diseases […]

Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660

Enrollment completion for the first Phase 3 clinical trial in microbiome industry Largest randomized, double-blinded study, with over 300 patients enrolled aimed to demonstrate the potential benefit of RBX2660 in reducing rates of recurrent Clostridioides difficile (C. diff) infection Rebiotix intends to use the results from the Phase 3 trial to serve as the basis […]

Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer

Phase 2 trial will evaluate combination of PD-1 inhibitor Libtayo® (cemiplimab-rwlc) and oncolytic virus Voyager-V1; preclinical research collaboration will explore new oncolytic virus treatments Vyriad to receive upfront payment and equity investment from Regeneron TARRYTOWN, N.Y., and ROCHESTER, Minn. (November 6, 2019) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Vyriad, Inc. today announced a research collaboration and option […]

Corvia Medical and physIQ Partner in Global Phase 3 Heart Failure Clinical Trial to Leverage Novel Digital Endpoints

The 100+ site global Phase 3 clinical trial is the first-of-its-kind to leverage continuous multivariate wearable sensor data and Artificial Intelligence-based analytics The landmark trial endpoint approach aligns with commentary at a recent FDA Public Workshop on biomarkers for heart failure clinical trials To date, hundreds of thousands of hours of continuous multivariate sensor data […]

SilkTech Biopharmaceuticals Completes Enrollment of Phase 2B Clinical Trial of SDP-4 for the Treatment of the Signs and Symptoms of Dry Eye Disease

MINNEAPOLIS, MN— August 6, 2019 — SilkTech Biopharmaceuticals, a biotechnology company focused on the development of novel therapies to treat Dry Eye Disease (DED), today announced the completion of their Phase 2B clinical trial enrollment to assess the safety and efficacy of the company’s SDP-4 ophthalmic eye-drop formulation to treat the signs and symptoms of DED. […]

SilkTech Biopharmaceuticals’ IND Submission Cleared by FDA; Phase 2 Clinical Trial Initiated for Patients with Dry Eye Disease

Milestone Results in $6.2 Million in Additional VC Funding Minneapolis, MN – April 16, 2019 – PRWeb – SilkTech Biopharmaceuticals, a company devoted to improving eye health through the development of silk-derived protein biotherapeutics for the targeted treatment of Dry Eye Disease (DED), today announced the company has received clearance of its Investigational New Drug […]

FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

One in Two Women in the United States Will Suffer a Fracture in Her Lifetime Due to Osteoporosis(1) EVENITY is the First and Only Bone Builder With a Dual Effect That Both Increases Bone Formation and Decreases Bone Loss(2) EVENITY Rapidly Reduces Fracture Risk and Builds New Bone With 12 Months of Therapy(2) THOUSAND OAKS, […]